The purpose of the study is to evaluate the effectiveness of selpercatinib in patients who have early-stage RET fusion-positive NSCLC and have already undergone surgery or radiation treatment. Participants in the study will be randomly assigned to receive either selpercatinib or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the trial.

Throughout the study, participants will be monitored to assess the progression of their condition and any potential side effects of the treatment. The trial aims to provide valuable information on whether selpercatinib can improve outcomes for patients with this specific type of lung cancer. The study is expected to continue for several years to gather comprehensive data on the treatment’s effectiveness and safety.

The purpose of this study is to determine if daily oral orforglipron is as effective as insulin glargine (an injectable insulin) in preventing major heart-related events in these patients. The study will look at outcomes such as myocardial infarction (heart attack), stroke, hospitalization for unstable angina (chest pain), and death related to heart disease.

This is a Phase 3, open-label study, which means participants and researchers will know which treatment is being given. Participants will either take orforglipron once daily by mouth or use insulin glargine injections while continuing their existing diabetes medications. The study will monitor their health status over time to compare the safety and effectiveness of these two treatment approaches.

During the study, participants will be monitored over a period of time to see how the medication affects the occurrence of major health events. These events include myocardial infarction, commonly known as a heart attack, stroke, or being hospitalized due to heart failure. The study also looks at coronary revascularization, which is a procedure used to improve blood flow to the heart, and any deaths caused by any reason.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

The purpose of the study is to see how effective and safe these treatments are for patients with this type of lung cancer. Participants will receive either rilvegostomig or pembrolizumab, along with chemotherapy drugs such as carboplatin and paclitaxel. The study will monitor how long patients live and how long they remain free from cancer progression, which means the cancer does not get worse. The study will also look at other factors like the overall response to the treatment and any side effects experienced.

Participants will receive their treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, and participants will have regular check-ups to monitor their health and the effects of the treatment. The goal is to find out which combination of treatments works best for this type of lung cancer.

The purpose of the study is to compare the effectiveness of different combinations of these treatments. Participants will receive either a combination of Dato-DXd and Pembrolizumab, with or without platinum-based chemotherapy, or a combination of Pembrolizumab, Pemetrexed, and platinum-based chemotherapy. The study aims to determine which combination works best in controlling the cancer and improving survival.

Participants in the study will receive their assigned treatments over a period of time, with regular monitoring to assess how the cancer responds to the treatment. The study will also involve the use of a placebo in some cases. The trial is designed to provide valuable information on the best treatment options for patients with this type of lung cancer, helping to improve future care and outcomes.

The purpose of the study is to compare how well RLY-2608 combined with fulvestrant works compared to capivasertib combined with fulvestrant in controlling the cancer and preventing it from getting worse. During the study, patients will be randomly assigned to one of the two treatment groups. They will continue receiving their assigned treatment for as long as it is helping them and they are not experiencing unacceptable side effects. Regular check-ups will be done to see how the cancer is responding to treatment using imaging scans, and to monitor for any side effects. Blood samples will be taken to measure the amount of medicine in the body.

The study will also look at how long people live, how many people respond to treatment, how long the response lasts, and whether the cancer remains stable for a certain period. Information will be collected about any unwanted effects that occur, including their severity and how they relate to the study medicines. The study will also assess how the treatment affects quality of life by using questionnaires that ask about symptoms and daily activities. The study is expected to start enrolling people in December 2025 and is planned to continue until July 2028.

The study is designed to see which treatment approach helps patients live longer, which is referred to as overall survival. Other factors being looked at include progression-free survival, which is the length of time during and after treatment that a disease does not get worse, and the time it takes for a disease to begin growing again. The study also monitors how the body responds to the medicine and any changes in symptoms like cough, chest pain, or dyspnea, which is the medical term for shortness of breath.

During the trial, participants are assigned to different groups to receive either the combination of medicines or a single medicine. Researchers will track how the drugs affect the body and any adverse events, which are unexpected or unpleasant side effects that occur during treatment. The study will also examine the amount of medicine present in the blood and how the body’s health and quality of life change over time.

The purpose of the study is to compare the effectiveness of different medication combinations in preventing the cancer from getting worse. One group will receive a combination of sotorasib, panitumumab, and FOLFIRI. FOLFIRI is a treatment plan that includes fluorouracil, irinotecan hydrochloride trihydrate, and calcium folinate, all of which are administered through intravenous use, meaning they are delivered directly into a vein. Another group will receive FOLFIRI either alone or combined with bevacizumab.

Participants will be assigned to one of these treatment groups to see which approach is better at managing the disease. The study will follow the progress of the cancer over time to observe how long the treatments keep the disease from spreading further or increasing in size.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

The cancer being investigated is also classified as advanced or metastatic, meaning it has grown beyond the original part of the lung or has spread to other parts of the body. Participants in this trial will receive their treatment through intravenous use, which involves delivering the medication directly into a vein using a liquid solution for infusion. The study will monitor how long the cancer remains stable without growing and the overall length of time patients live during the trial.

The purpose of this study is to find out if adding bleximenib to the standard intensive chemotherapy treatment can help patients live longer without their disease getting worse compared to receiving standard chemotherapy with placebo. The standard treatment includes chemotherapy to put the disease into remission, followed by additional chemotherapy to strengthen this response, and then maintenance therapy to help keep the disease under control.

During the study, patients will receive either bleximenib or placebo together with their regular intensive chemotherapy treatment. The study follows patients through the initial treatment phase aimed at achieving remission, a consolidation phase to reinforce the response, and then a maintenance phase. Neither the patients nor their doctors will know whether they are receiving bleximenib or placebo during the study. The study will monitor how well the treatment works and track patient outcomes over time.

Participants in this study will take the study medication for about three years. During this time, they will have regular visits where blood tests will be done to measure how well their kidneys are working. These measurements will help researchers understand if the medication is helping to slow down the loss of kidney function. Some participants will also have imaging scans to measure the size of their kidneys after one year of treatment. The study is designed for adults between 18 and 60 years of age who have signs that their kidney disease is getting worse more quickly than usual.

Throughout the study, doctors will monitor participants for any unwanted effects of the medication and will check how the kidneys are responding to treatment. After completing the treatment period, participants will have follow-up visits where additional measurements will be taken to see what happens after stopping the medication. The study will collect information about serious health problems and specific side effects that may be related to the treatment. All of this information will help researchers understand whether this medication could be a useful treatment option for people living with polycystic kidney disease.

The purpose of the study is to find out if adding BMS-986504 to pembrolizumab and chemotherapy can help people with this type of lung cancer live longer without their cancer getting worse, and to see if it can help them live longer overall, compared to treatment with placebo plus pembrolizumab and chemotherapy. The study will also look at how well the cancer responds to treatment and how long any response lasts, as well as checking for any unwanted effects that the treatments may cause.

The study will be conducted in two phases. Participants will be randomly assigned to receive either BMS-986504 or placebo, both given together with pembrolizumab and chemotherapy. The specific chemotherapy medicines used will depend on the type of lung cancer each person has. Throughout the study, doctors will perform regular check-ups and scans to see how the cancer is responding to treatment and to monitor for any side effects. Treatment will continue for as long as it is helping and not causing unacceptable side effects.

The study tests whether olpasiran is more effective than a placebo in reducing the risk of serious heart-related events. These events include coronary heart disease death, myocardial infarction (heart attack), and emergency procedures to restore blood flow to the heart. The medication is being studied specifically in people who have high levels of lipoprotein(a) in their blood and are considered at risk for heart problems.

During the study, participants will receive either olpasiran or a placebo while continuing their usual heart medications. The study will track any heart-related events that occur and measure how the treatment affects the amount of lipoprotein(a) in the blood. This research is part of a larger program called OCEAN(a)-PreEvent, which aims to better understand how to prevent first-time heart problems in people with high lipoprotein(a) levels.

The medication is given as a solution for injection under the skin (subcutaneous use). During the study, participants will receive either maridebart cafraglutide or placebo. The study will track important heart-related events that may occur, such as heart attacks, strokes, and the need for heart procedures.

The research team will monitor participants’ health throughout the study, focusing particularly on heart and blood vessel-related events. The study will look at whether the medication can help prevent serious heart problems and improve survival rates in people who have both cardiovascular disease and weight issues.

The purpose of the study is to evaluate how well these treatments work in preventing serious heart-related events, such as heart attacks, strokes, and heart failure. Participants in the study will be randomly assigned to receive either the intensified treatment or the standard treatment. The study will monitor the time it takes for participants to experience any major heart-related events, such as cardiovascular death, non-fatal heart attacks, or hospitalizations due to heart issues.

The trial is expected to run for several years, with the goal of gathering enough data to determine the effectiveness of the intensified treatment approach. By participating in this study, researchers hope to find better ways to manage heart health and prevent future heart-related problems in individuals who have already experienced a heart attack.

Participants in the study will receive either the new medication, Ustekinumab, or a placebo. The new medication, JNJ-77242113, is taken as a film-coated tablet, while Ustekinumab is given as an injection. The study will last for several weeks, during which participants will be monitored to see how their psoriasis responds to the treatment. The goal is to see if the new medication can improve the symptoms of psoriasis, such as reducing the size and severity of the skin patches.

The study will involve regular check-ups to assess the condition of the skin and overall health. Participants will be randomly assigned to one of the treatment groups, and neither the participants nor the researchers will know which treatment is being given to ensure unbiased results. The study aims to provide valuable information on whether JNJ-77242113 is a safe and effective option for treating moderate to severe plaque psoriasis.

The purpose of the study is to determine if adding venetoclax to the treatment with ivosidenib and azacitidine can improve outcomes for patients with newly diagnosed IDH1-mutated AML who are not eligible for intensive chemotherapy. The study will involve taking these medications in the form of film-coated tablets or injections over a period of time. Some patients will receive a placebo, which looks like the real medication but does not contain the active drug, to compare the effects.

Participants in the study will be monitored to see how their condition responds to the treatment. The study will track how long patients remain free of disease progression, as well as other factors like overall survival and quality of life. The trial aims to provide valuable information on whether this combination of medications can offer a new treatment option for patients with this specific type of AML.

The purpose of the study is to determine if the combination of Acasunlimab and Pembrolizumab is more effective than Docetaxel in treating patients with NSCLC. Participants in the study will receive either the combination of Acasunlimab and Pembrolizumab or Docetaxel. The study will monitor the overall survival of participants, which means how long they live after starting the treatment. It will also look at other factors like how long the cancer does not get worse, the response of the cancer to the treatment, and any side effects experienced by the participants.

The study will take place over several years, and participants will be closely monitored throughout the process. The trial aims to provide valuable information on whether the new combination of treatments can offer better outcomes for patients with NSCLC compared to the current standard treatment. This research is important for developing more effective therapies for lung cancer patients in the future.

The purpose of the study is to determine if this combination of medications can help improve the overall survival of patients with this specific type of AML. Participants in the study will receive either the combination of Revumenib, Azacitidine, and Venetoclax or a placebo along with Azacitidine and Venetoclax. The study will last for a period of up to 76 weeks, during which the effects of the treatment will be monitored. The medications will be administered in the form of tablets taken orally, and Azacitidine will be given as an injection.

This trial aims to provide valuable information on whether the addition of Revumenib can enhance the effectiveness of the existing treatment for patients with these specific genetic changes in AML. The study will also look at various outcomes, such as the time it takes for the treatment to start working, the duration of the response, and the quality of life of the participants. The results will help in understanding the potential benefits and safety of this new treatment approach for patients with AML who cannot undergo intensive chemotherapy.

The purpose of the study is to evaluate how effective and safe the ICEF15 treatment is for people with fecal incontinence caused by problems with the external anal sphincter, a muscle that helps control bowel movements. Participants in the study will receive either the ICEF15 treatment or a placebo, which is a solution that does not contain the active treatment. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will receive injections and will be monitored over a period of time to see if there is a reduction in the frequency of incontinence episodes. The study aims to determine if the treatment can reduce these episodes by at least 50% compared to before the treatment started. This research is important for finding new ways to help people manage fecal incontinence and improve their quality of life.

Participants in the study will be randomly assigned to one of two groups. One group will receive the standard hormone therapy alone, while the other group will receive both the standard hormone therapy and Palbociclib. The treatment with Palbociclib will last for two years, while the hormone therapy will continue for at least five years. The study will monitor participants over time to see how well they do with each treatment approach, focusing on how long they remain free from invasive breast cancer.

The trial aims to provide valuable information about the potential benefits of combining Palbociclib with hormone therapy for patients with HR+/HER2- early breast cancer. By comparing the two treatment groups, researchers hope to learn more about the effectiveness and safety of this combination therapy. The study is expected to continue until the end of 2028, allowing for a comprehensive evaluation of the long-term outcomes for participants.

The purpose of the study is to see how well Ifinatamab deruxtecan works compared to chemotherapy in treating SCLC. Participants in the study will receive either Ifinatamab deruxtecan or a treatment chosen by their doctor, which may include Topotecan or other chemotherapy options. The study will monitor how the cancer responds to the treatment and how long patients live after starting the treatment. This will help researchers understand if the new treatment is more effective than the current options.

Participants will receive their assigned treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for a period of time, during which patients will have regular check-ups to monitor their health and the progress of their cancer. The trial aims to provide valuable information that could lead to better treatment options for people with relapsed SCLC in the future.

The purpose of the study is to assess how well JDQ443 works and how safe it is for patients with this specific type of lung cancer. The study will include patients whose cancer has spread locally or to other parts of the body, and who have not received any previous treatment for their advanced cancer. The study will also consider the presence of another genetic factor called PD-L1 expression, which can be either less than 1% or 1% and above, and may include an additional genetic change known as an STK11 co-mutation.

Participants in the study will take JDQ443 orally, and the study will monitor their response to the treatment over time. The study aims to understand the overall response rate, which is the proportion of patients who experience a reduction in their cancer size. It will also look at how long the response lasts, the time it takes for the cancer to progress, and overall survival rates. Additionally, the study will track any side effects or changes in health indicators such as laboratory values and vital signs. The trial is expected to continue until October 2025.

The purpose of the study is to determine if the BrECADD treatment is less toxic than the escalated BEACOPP treatment while maintaining similar effectiveness. Participants will receive either 4 to 6 cycles of the escalated BEACOPP or 4 to 6 cycles of BrECADD, followed by radiotherapy if there are any remaining cancerous areas detected by a PET scan, which is a type of imaging test. The study aims to assess the safety and effectiveness of these treatments in terms of reducing treatment-related side effects and preventing the cancer from worsening.

Throughout the study, participants will be monitored for various outcomes, including how well the cancer responds to treatment, overall survival rates, and any side effects experienced. The study will also look at the quality of life of participants and the occurrence of any new cancers. The trial is designed to provide valuable information on optimizing treatment for patients with advanced Hodgkin Lymphoma, aiming to improve patient outcomes and reduce the burden of treatment side effects.

The main purpose of this research is to determine if giving isatuximab as an injection under the skin works as well as giving it through an intravenous infusion when combined with the other medications. The study will compare these two methods in patients who are eligible for stem cell transplantation.

During the treatment, patients will receive one of the two forms of isatuximab along with the standard combination of medications. The treatment period will last up to 18 months. Throughout the study, doctors will monitor how well the treatment is working by measuring the amount of myeloma cells in the body and checking for signs that the disease is responding to the therapy.

Participants in the study will be randomly assigned to one of the two treatment groups. The treatments will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will last for a period of up to 12 months, during which time patients will receive regular treatments and be monitored for any changes in their condition. The study will also include a group of patients who will receive a placebo, which is a substance with no active medication, to compare the effects of the treatments.

The trial aims to provide valuable information on the effectiveness of these treatment combinations in managing advanced stomach cancer. By comparing the two groups, researchers hope to determine which combination offers better outcomes in terms of survival and response to treatment. This study is important for developing new strategies to treat patients with this type of cancer, especially those who have not had success with previous therapies.

The purpose of the study is to compare how well patients respond to treatment with olaparib alone versus a combination of olaparib, durvalumab, and UV1. Olaparib is taken as tablets by mouth, durvalumab is given through an intravenous infusion (through a vein), and UV1 is given as an injection under the skin. The medications work in different ways to help control the cancer – olaparib targets cancer cells directly, durvalumab helps the immune system fight cancer, and UV1 is designed to stimulate the body’s immune response against cancer cells.

During the study, patients will be randomly assigned to receive either olaparib alone or the combination of all three medications. The treatment period can last up to 36 months, during which patients will have regular check-ups to monitor their health and how well the treatment is working. Throughout the study, doctors will track if the cancer stays under control and measure how long patients live without their cancer getting worse.

The purpose of the study is to compare the overall survival of patients who receive the combination of SBP-101, nab-paclitaxel, and gemcitabine with those who receive only nab-paclitaxel and gemcitabine. Participants will be randomly assigned to one of the two groups, and neither the participants nor the researchers will know who is receiving SBP-101 or the placebo. The study will involve regular visits to the clinic for treatment and monitoring, and participants will receive the medications through injections or infusions.

The study will continue for a period of time, during which the health and progress of the participants will be closely monitored. The main goal is to see if the addition of SBP-101 can improve the length of time patients live with this type of cancer. The study will also look at other factors, such as how long it takes for the cancer to progress and the overall response to the treatment. Participants will be asked to complete questionnaires about their quality of life during the study.

The purpose of the study is to evaluate how well CPX-351 works compared to the standard chemotherapy in terms of overall survival, which means how long patients live after starting treatment. The study will involve patients receiving their assigned treatment and being monitored over time to see how they respond. Some patients may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments more accurately.

Participants in the study will receive their treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will last for several months, with regular check-ups to monitor the patients’ health and response to the treatment. The goal is to find out if CPX-351 can improve survival rates for patients with AML compared to the standard treatment options currently available.

The purpose of the study is to determine if adding bemarituzumab to standard chemotherapy and nivolumab treatment improves survival for patients with previously untreated advanced stomach cancer. The medications are given through intravenous infusion, except for capecitabine which is taken by mouth. The study is conducted in two parts: a smaller initial phase to evaluate safety, followed by a larger phase to compare the effectiveness of the treatments.

During the study, participants will receive regular doses of the study medications and undergo various medical assessments. The treatment period may last for several months, depending on how well the participant responds to the therapy. Doctors will monitor participants’ health status, check for side effects, and evaluate how well the cancer responds to treatment throughout the study period.

Participants in the study will receive either the new treatment combination or the standard treatment. The new treatment involves the use of Dato-DXd, a medication designed to target and destroy cancer cells, and Durvalumab, which helps the immune system fight cancer. These medications will be given through an intravenous infusion, which means they are delivered directly into the bloodstream. The standard treatment includes Pembrolizumab, another medication that boosts the immune system, along with chemotherapy, which uses drugs to kill cancer cells. Some participants may also receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments.

The study will follow participants over a period of time to monitor their response to the treatments. This includes checking for the absence of cancer in the breast and lymph nodes after surgery, as well as tracking the time until any signs of cancer return or other health events occur. The goal is to see if the new treatment can improve outcomes for patients with these specific types of breast cancer. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

Participants in the study will receive one of the treatment combinations and will be monitored over a period of time to assess the effectiveness of the treatment. The study is designed to be “double-blind,” meaning neither the participants nor the researchers know who is receiving which treatment, to ensure unbiased results. The treatments are administered orally, and the study will last for a maximum of 26 weeks. Throughout the study, participants will have regular check-ups and tests to monitor their health and the progress of the treatment.

This trial aims to provide valuable information on the best treatment options for patients with this specific type of breast cancer. By comparing the two treatment combinations, researchers hope to find a more effective way to manage the disease and improve patient outcomes. The study is part of ongoing efforts to advance cancer treatment and provide better care for patients with advanced breast cancer.

Participants in the study will be randomly assigned to receive either the combination of Zibotentan and Dapagliflozin or Dapagliflozin alone. Some participants may receive a placebo. The study will last for about 24 months, during which time participants will take the medication orally, in the form of a film-coated tablet. Throughout the study, participants will have regular check-ups to monitor their kidney function and overall health. The main focus will be on changes in kidney function over time, as well as other health indicators related to kidney disease.

This study aims to provide valuable information on whether the combination of Zibotentan and Dapagliflozin can offer better protection for the kidneys in people with Chronic Kidney Disease and High Proteinuria. By participating, individuals will contribute to research that could lead to improved treatments for this condition in the future.